|1.||Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated)
|3.||T-Cell Leukemia (Leukemia, T Cell)
|1.||Utsunomiya, Atae: 46 articles (12/2015 - 02/2002)|
|2.||Yamada, Yasuaki: 36 articles (01/2015 - 01/2002)|
|3.||Mori, Naoki: 28 articles (10/2013 - 02/2002)|
|4.||Tomonaga, Masao: 28 articles (03/2012 - 01/2002)|
|5.||Tanaka, Yuetsu: 26 articles (12/2014 - 09/2002)|
|6.||Hermine, Olivier: 25 articles (01/2015 - 01/2002)|
|7.||Kamihira, Shimeru: 25 articles (12/2012 - 01/2002)|
|8.||Ohshima, Koichi: 24 articles (11/2015 - 03/2003)|
|9.||Tsukasaki, Kunihiro: 23 articles (12/2015 - 09/2002)|
|10.||Ishida, Takashi: 23 articles (11/2015 - 09/2003)|
|1.||Zidovudine (Retrovir)FDA LinkGeneric
01/01/1990 - "The antiviral effect of zidovudine was examined in an experimental model of adult T cell leukemia in rabbits. "
01/01/1990 - "Antiviral effect of zidovudine in the experimental model of adult T cell leukemia in rabbits."
03/01/2005 - "Recently, antiretroviral therapy using the combination of zidovudine (AZT) and interferon alpha (IFN-alpha) has been shown to induce a high complete remission rate and to prolong the survival of ATLL patients. "
12/10/2011 - "Use of zidovudine (ZDV) and interferon alfa (IFN-α) has been associated with improved response rates in small studies and prolonged overall survival in leukemic ATLL subtypes in a recent meta-analysis. "
12/01/2012 - "In a recent meta-analysis the use of zidovudine and interferon alpha (ZDV/IFN) has been associated with improved response rates and prolonged overall survival in leukemic subtypes of ATLL (both acute and Chronic) confirmed in a multivariate analysis. "
|2.||Interferon-alpha (Interferon Alfa)FDA Link
10/01/1988 - "The phase II trial of natural interferon-alpha (HLBI) in treatment of adult T-cell leukemia was carried out as a cooperative study. "
10/01/1988 - "[Clinical study on the effect of natural alpha-interferon (HLBI) in the treatment of adult T-cell leukemia]."
12/28/2007 - "Stem cell properties and the side population cells as a target for interferon-alpha in adult T-cell leukemia/lymphoma."
04/01/1990 - "A case of adult T cell leukemia associated with prominent skin infiltrations was treated with native alpha-interferon (Human lymphoblastoid interferon; HLBI). "
12/15/1988 - "Adult T-cell leukemia and interferon-alpha."
04/01/1993 - "MST-16 was shown to be effective in ATLL, which has no standard therapy. "
01/01/1992 - "Effective treatment of adult T cell leukemia/lymphoma with a novel oral antitumor agent, MST-16."
04/01/1993 - "Treatment of adult T-cell leukemia/lymphoma with MST-16, a new oral antitumor drug and a derivative of bis(2,6-dioxopiperazine). "
01/01/1992 - "Orally administered MST-16 is a promising agent for the treatment of ATLL."
01/01/1992 - "Six patients with ATLL were treated with a new antitumor agent, MST-16, which is a derivative of bis(2,6-dioxopiperazine). "
12/28/2007 - "On the other hand, treatment with interferon (IFN)-alpha is sometimes effective in ATLL, particularly combined with other drugs. "
12/01/2001 - "Possible involvement of interferon regulatory factor 4 (IRF4) in a clinical subtype of adult T-cell leukemia."
03/01/1985 - "Among virus-associated cell lines, only Epstein-Barr virus-associated B-cell lines were sensitive to the interferon; adult T-cell leukemia virus-associated T-cell lines were not sensitive. "
06/01/2004 - "Hemophagocytic syndrome as a presenting sign of transformation of smoldering to acute adult T-cell leukemia/lymphoma: efficacy of anti-retroviral and interferon therapy."
01/01/2002 - "We summarize recent studies on the activation and regulation of interferon (IFN) regulatory factor-4 (IRF-4) and its function in activated T cells, human T cell lymphoma virus (HTLV-I)-infected T cells, and HTLV-I-induced adult T cell leukemia (ATL). "
|5.||Etoposide (VP 16)FDA LinkGeneric
01/01/2014 - "Thus, combined therapy with mogamulizumab plus etoposide is considered to be effective for resolution of the cutaneous nodular masses in patients with ATLL. "
09/01/1993 - "[Adult T cell leukemia/lymphoma effectively treated with chronic oral etoposide]."
01/01/2014 - "A case of post-mogamulizumab relapse of acute-type adult T-cell leukemia/lymphoma successfully treated with mogamulizumab and etoposide."
03/01/2013 - "Combination of skin-directed therapy and oral etoposide for smoldering adult T-cell leukemia/lymphoma with skin involvement."
09/01/2001 - "[Low-dose etoposide in a patient with adult T-cell leukemia/lymphoma who had severe complications]."
|6.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/01/2006 - "Eight ATLL patients underwent unrelated BMT; five received the conventional conditioning regimen consisting of cyclophosphamide and total body irradiation, while three received a reduced-intensity preparative regimen. "
01/01/2002 - "A 47-year-old woman with adult T-cell leukemia in remission was treated with high-dose cyclophosphamide as a preparative regimen for allogeneic bone marrow transplantation. "
12/01/1987 - "A 43-year-old patient with adult T cell leukemia (ATL) was treated with mega-dose cyclophosphamide and total body irradiation (TBI) followed by bone marrow transplantation (BMT) from his HLA-identical sibling who was not a carrier of ATL virus. "
12/01/1987 - "Treatment of adult T cell leukemia with mega-dose cyclophosphamide and total body irradiation followed by allogeneic bone marrow transplantation."
07/01/1995 - "Two patients developed acute leukemia; however, one had adult T-cell leukemia associated with human T-lymphotrophic virus type 1 (HTLV-1) and a second patient developed AML after receiving additional cyclophosphamide for metastatic breast cancer. "
|7.||Vincristine (Oncovin)FDA LinkGeneric
09/01/1987 - "[A case of adult T-cell leukemia achieving complete remission with epirubicin, vincristine and prednisolone chemotherapy]."
12/01/2003 - "We report a case of human T-cell lymphotropic virus 1 (HTLV-1)-associated adult T cell leukemia/lymphoma (ATL) in clinical remission > 1 year after therapy with denileukin diftitox and hyper-CVAD (hyperfractionated cyclophosphamide/doxorubicin/vincristine/decadron). "
08/01/1991 - "Thirty patients with refractory lymphoid malignancies [multiple myeloma (MM): 8, plasma cell leukemia (PCL): 2, acute lymphocytic leukemia (ALL): 5, chronic myelogenous leukemia in blast crisis: 1, chronic lymphocytic leukemia in blast crisis: 1, adult T-cell leukemia: 1, non-Hodgkin lymphoma (NHL): 9, Hodgkin's disease (HD): 3] were treated with VAD regimen (vincristine, doxorubicin, dexamethasone). "
12/01/2007 - "To test the superiority of VCAP-AMP-VECP over biweekly cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), we conducted a randomized controlled trial exclusively for ATLL. "
12/01/1999 - "Long-term maintenance combination chemotherapy with OPEC/MPEC (vincristine or methotrexate, prednisolone, etoposide and cyclophosphamide) or with daily oral etoposide and prednisolone can improve survival and quality of life in adult T-cell leukemia/lymphoma."
01/01/2014 - "Results of flow cytometry analysis of peripheral blood indicated ATLL and antibodies to human T-lymphotropic virus type 1 (HTLV-1) were detected. "
01/01/2012 - "We developed various antibodies as diagnostic tools to identify CADM1<sup>+</sup> ATLL cells. "
09/01/2001 - "The lower level of AAV-2 seropositivity in ATLL-patients may indicate that AAV-2 antibody-positive HTLV-I carriers might be less likely to develop ATLL or that loss of AAV-2 antibodies may parallel the development of disease."
01/01/1996 - "These morphologic and phenotypic features were compatible with adult T-cell leukemia, but serum antibodies to human T-cell lymphotropic virus type I (HTLV-I) were not detected by the particle aggregation method and an enzyme-linked immunosorbent assay. "
01/01/1996 - "[Case of adult T-cell leukemia without antibodies for HTLV-I but with for pX gene region]."
|9.||DNA (Deoxyribonucleic Acid)IBA
07/01/2001 - "Immunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus)."
04/01/2004 - "This study was designed to determine whether DNA hypomethylation-associated aberrant gene expression is involved in adult T-cell leukemia (ATL) leukemogenesis. "
03/01/1998 - "Studies also revealed the existence of HTLV-1 provirus DNA in nuclei of sweat gland epithelial cells and vascular endothelial cells as well as lymphoid cells in ATLL patients. "
01/01/1987 - "Later studies showed that 1) the geographical distribution of HAM follows that of adult T-cell leukemia (ATL) and 2) viruses detected in both disorders were identical by DNA blotting assay, but HAM and ATL are definitely expressed clinically as distinct from the other. "
12/01/2015 - "SIRT1 downregulation enhances chemosensitivity and survival of adult T-cell leukemia-lymphoma cells by reducing DNA double-strand repair."
|10.||arsenic trioxide (Trisenox)FDA Link
01/01/2009 - "This unexpected result with a multitreated/chemorefractory disease led us to reconsider the potential therapeutic benefits of arsenic trioxide, which has demonstrated efficacy against ATLL cells."
01/01/2006 - "Lung infiltration of adult T-cell leukemia cells following the administration of arsenic trioxide. "
12/15/2001 - "Fluorescence-activated cell sorter analysis, fluorescence microscopy, and measures of mitochondrial membrane potential (Delta Psi m) demonstrated that arsenic trioxide alone was sufficient to induce programmed cell death in all HTLV-1 and -2 cells tested and in ATLL patient samples. "
12/15/2001 - "The recent report that arsenic trioxide induces apoptosis in HTLV-1-transformed cells prompted investigation of the mechanism of action of this drug in HTLV-1 and HTLV-2 interleukin-2-independent T cells and in HTLV-1-immortalized cells or in ex vivo ATLL samples. "
05/01/2002 - "Arsenic trioxide (As2O3) has been reported to induce apoptosis in human T-cell leukemia virus type-I (HTLV-I) infected T-cell lines and fresh adult T-cell leukemia (ATL) cells and to induce G1 phase accumulation in HTLV-I infected T-cell lines. "
|1.||Drug Therapy (Chemotherapy)
04/01/1997 - "Chemotherapy for adult T-cell leukemia (ATL) has been reported to fail to induce complete remission because of drug resistance in most patients. "
12/01/2010 - "We present 2 patients diagnosed with ATLL who were treated with hyper-CVAD chemotherapy and have achieved a durable complete remission. "
01/01/1997 - "The purpose of this study was to clarify the clinical efficacy of multidrug chemotherapy for aggressive adult T-cell leukemia (ATL). "
12/01/2012 - "Combined first line therapy prolonged median OS in acute (p = 0.0081) and lymphomatous ATLL (p = 0.001).These data support the use of low dose ZDV/IFN with chemotherapy as first line treatment for patients with newly diagnosed aggressive ATLL. "
08/01/2012 - "For ATLL, she was serially treated with CHOP chemotherapy, an LSG 15 protocol, and CytaBOM protocol with consequent partial remission. "
|2.||Hematopoietic Stem Cell Transplantation
06/01/2008 - "Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has proven effective in adult T-cell leukemia/lymphoma (ATL) patients. "
06/01/2007 - "Small number of HTLV-1-positive cells frequently remains during complete remission after allogeneic hematopoietic stem cell transplantation that are heterogeneous in origin among cases with adult T-cell leukemia/lymphoma."
10/01/2009 - "A 25-year-old female developed ATLL and underwent allogeneic hematopoietic stem cell transplantation (HSCT) in non-remission. "
01/01/2001 - "Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation."
01/01/2013 - "Since allogeneic hematopoietic stem-cell transplantation (allo-HSCT) has been introduced as a modality with curative potential during study period, we also evaluated the association of the annual number of allo-HSCT and the trend of the mortality of ATLL. "
|3.||Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)
07/01/1999 - "Molecular remission in adult T cell leukemia after autologous CD34+ peripheral blood stem cell transplantation."
02/01/2012 - "A 56-year-old woman with Hodgkin-like adult T-cell leukemia/lymphoma was treated with allogeneic peripheral blood stem cell transplantation on 17 April 2009. "
05/01/2006 - "She suffered from adult T-cell leukemia and received peripheral blood stem cell transplantation (PBSCT). "
02/01/2012 - "Epstein-Barr virus-associated post-transplant lymphoproliferative disorders after allogeneic peripheral blood stem cell transplantation for Hodgkin-like adult T-cell leukemia/lymphoma."
12/01/2005 - "Prolonged remission of adult T-cell leukemia/lymphoma treated with interferon-gamma following autologous peripheral blood stem cell transplantation."
|4.||Combination Drug Therapy (Combination Chemotherapy)
08/01/2013 - "Here we report a woman with ATLL resistant to combination chemotherapy, who achieved complete remission following treatment with mogamulizumab and subsequently received allogeneic HSCT. "
04/01/1999 - "All 4 Ss-infected (Ss-positive) ATLL patients treated with combination chemotherapy achieved complete remission (CR) versus only 2 of 7 Ss-negative ATLL patients (p = .04). "
11/01/1999 - "He was diagnosed to have ATLL and, despite an initial response, became resistant to combination chemotherapy. "
04/01/1999 - "By comparison with other ATLL patients studied for p53 expression, P53-positive ATLL were characterized by a lower response rate to combination chemotherapy (CR: 0 of 6 versus 4 of 6; p = .04) and a shorter survival (2 versus 9 months, p = .04). "
08/01/1994 - "[A pilot study of alternate combination chemotherapy with rhG-CSF for adult T-cell leukemia/lymphoma]."
06/01/2012 - "In this study, we review previous reports and discuss the role of DLIs in the treatment of post-transplant relapsed ATLL."
12/01/2014 - "In conclusion, CBT cures patients with ATLL partly through a graft-versus-ATLL effect. "
06/01/2008 - "These data suggested the presence of a graft-versus-ATLL effect and the feasibility of a transplant procedure without ATG in elderly ATLL patients, but could not demonstrate the clinical benefit of incorporating ATG."
08/01/2007 - "It is clear that a graft-versus-ATLL effect is present after alloSCT, regardless of the conditioning regimen or the stem cell source."
06/01/2005 - "After the allo-BMT transplant, a graft-versus-ATLL (GVATLL) effect may be induced by abrupt discontinuation of immunosuppression."